Dermatosis eritematoescamosa generalizada

Rocío Orquídea Miguens Pawelek; Graciela Sánchez; Karina Cejas; Diego Silva

doi:10.47196/da.v31i1.2769

Authors

Rocío Orquídea Miguens Pawelek Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina
Graciela Sánchez Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina
Karina Cejas Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina
Diego Silva Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v31i1.2769

Keywords:

generalized erythematous scaly dermatosis

Abstract

A 54-year-old male patient with a history of glaucoma, treated with timolol 0.5% eye drops and escitalopram 10 mg/day, with no history of allergies, consulted for an erythematous scaly dermatosis of 8 years' duration, which, due to exacerbations and without medical supervision, was periodically treated with meprednisone 4 mg/day.

On physical examination, he presented follicular papules that formed plaques with mild scaling predominantly on the face, upper torso, upper limbs, inguinal fold and lumbar area with marked extension. In addition, several achromic macules with irregular borders were observed on the right lower limb over the calf region, with a previous diagnosis of vitiligo. There was no palmoplantar or mucous membrane involvement.

Author Biographies

Rocío Orquídea Miguens Pawelek, Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina

Physician, Dermatology Service of the Dr. Abel Zubizarreta Hospital

Graciela Sánchez, Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina

Head of the Department of Anatomical Pathology, Department of Dermatology of the Dr. Abel Zubizarreta Hospital

Karina Cejas, Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina

Staff Physician, Dermatology Service of the Dr. Abel Zubizarreta Hospital

Diego Silva, Dr. Abel Zubizarreta Hospital, City of Buenos Aires, Argentina

Head of the Dermatology Service, Dermatology Service of the Dr. Abel Zubizarreta Hospital

References

I. Mancilla-Gudiel P, Arenas R. Pityriasis rubra pilaris: una revisión. Dermatología CMQ. 2020;18:53-60.

II. Maloney NJ, Hisaw LD, Worswick S. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab or ustekinumab: a retrospective investigation. Dermatol Ther. 2017;30:e12559.

III. García-Briz MI, García-Ruiz R, Zayas-Gávila AI, Mateu-Puchades A. Pityriasis rubra pilaris. ¿Algo más que un trastorno de la queratinización? Med Cutan Iber Lat Am. 2018; 46:7-12.

IV. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris. A review of diagnosis and treatment. Am J Clin Dermatol. 2010;11:157-170.

V. Boyd A, Polcari I. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris. Pediatr Dermatol. 2018;35;62-63.

VI. Bella-Navarro R, Pellicer-Oliver ZM, Martín-Hernández JM, Jordá-Cuevas E. Pityriasis rubra pilaris. Diagnóstico y tratamiento. Piel. 2013;28:20-30.

VII. Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17:243-259.